Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa Read more about Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa
Registry of Asthma Patients Initiating DUPIXENT® Read more about Registry of Asthma Patients Initiating DUPIXENT®
ACTIV-3: Therapeutics for Inpatients With COVID-19 Read more about ACTIV-3: Therapeutics for Inpatients With COVID-19
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) Read more about A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE Read more about Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Read more about Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults Read more about Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed Read more about A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed
Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Read more about Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers Read more about TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers